Program
GENSCI142
A development code. Also written as “GenSci142 capsule” and “GenSci142”.
Its studies are mostly in Vaginosis, Bacterial, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 22 open or running | phase 1since Nov 27, 2025 | Nov 27, 2025 | Jan 5, 2027phase 1 · NCT07663838 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2025First study: phase 1 study in Vaginosis, BacterialFirst studyNCT07302035 · 30 planned · China
- Jun 5, 2026Phase 1 study in Vaginosis, BacterialNCT07663838 · 42 planned · China
Ahead
- Jan 5, 2027Primary completion: phase 1 study in Vaginosis, BacterialNCT07663838
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07663838Vaginosis, Bacterial · China | 1 | Recruiting | Jan 5, 2027 | 42 |
| NCT07302035Vaginosis, Bacterial · China | 1 | Not yet recruiting | Sep 2026 | 30 |
How it is read
Names in the registry
- “GenSci142 capsule”, 1 entry
- “GenSci142”, 1 entry
Codes read as this program: GENSCI142.
Conditions, from the studies’ own filings
- Vaginosis, Bacterial, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.